{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:55:17Z","timestamp":1792688117093,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015544","name":"King's College Hospital Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.06.017","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:23:50Z","timestamp":1783682630000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1761-0544","authenticated-orcid":false,"given":"Mark","family":"Gibson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Adas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Muzafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaad","family":"Muzafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"De Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Chavali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mootoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Bechman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Phillippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Welton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.06.017_bib0001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3899\/jrheum.091461","article-title":"Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities","volume":"85","author":"El-Gabalawy","year":"2010","journal-title":"J Rheumatol Suppl."},{"issue":"9","key":"10.1016\/j.ard.2026.06.017_bib0002","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"issue":"22","key":"10.1016\/j.ard.2026.06.017_bib0003","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ard.2026.06.017_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.ard.2026.06.017_bib0005","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med."},{"issue":"13","key":"10.1016\/j.ard.2026.06.017_bib0006","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.ard.2026.06.017_bib0007","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"21","key":"10.1016\/j.ard.2026.06.017_bib0008","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med."},{"issue":"10341","key":"10.1016\/j.ard.2026.06.017_bib0009","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.ard.2026.06.017_bib0010","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"10188","key":"10.1016\/j.ard.2026.06.017_bib0011","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.ard.2026.06.017_bib0012","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-023-00370-7","article-title":"Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study","volume":"8","author":"de Souza","year":"2024","journal-title":"BMC Rheumatol."},{"issue":"10464","key":"10.1016\/j.ard.2026.06.017_bib0014","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(24)02151-2","article-title":"Driving down the cost of biologics: lessons from a nationalised health-care system","volume":"404","author":"Russell","year":"2024","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.ard.2026.06.017_bib0015","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S2665-9913(24)00002-X","article-title":"The influence of safety warnings on the prescribing of JAK inhibitors","volume":"6","author":"Russell","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.06.017_bib0016","unstructured":"Drugs.com. Generic Xeljanz availability and release date [Internet]. 2025. Accessed 2026 Feb 2. Available from: https:\/\/www.drugs.com\/availability\/generic-xeljanz.html."},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mayocp.2023.08.029","article-title":"Real-world clinical equivalence of generic and branded tofacitinib: a prospective longitudinal cohort study in patients with rheumatoid arthritis","volume":"99","author":"Zhao","year":"2024","journal-title":"Mayo Clin Proc."},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0018","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther."},{"issue":"12","key":"10.1016\/j.ard.2026.06.017_bib0019","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol."},{"issue":"4","key":"10.1016\/j.ard.2026.06.017_bib0020","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.semarthrit.2018.05.009","article-title":"Malignancy development risk in psoriatic arthritis patients undergoing treatment: a systematic review and meta-analysis","volume":"48","author":"Luo","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.06.017_bib0021","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.ard.2026.06.017_bib0022","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis."},{"issue":"18","key":"10.1016\/j.ard.2026.06.017_bib0023","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199011013231802","article-title":"Ulcerative colitis and colorectal cancer. A population-based study","volume":"323","author":"Ekbom","year":"1990","journal-title":"N Engl J Med."},{"issue":"19","key":"10.1016\/j.ard.2026.06.017_bib0024","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA."},{"key":"10.1016\/j.ard.2026.06.017_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436581","article-title":"Immune-mediated inflammatory diseases and cancer - a dangerous liaison","volume":"15","author":"Maier","year":"2024","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.ard.2026.06.017_bib0026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jbspin.2016.02.028","article-title":"Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers","volume":"84","author":"de La Forest Divonne","year":"2017","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0027","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12935-021-02325-9","article-title":"Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0028","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.ard.2026.06.017_bib0029","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.ard.2026.06.017_bib0030","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.017_bib0031","unstructured":"EMA. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders [Internet]. 2023. Accessed 2026 Feb 2. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/referral\/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_en.pdf-0."},{"key":"10.1016\/j.ard.2026.06.017_bib0032","unstructured":"FDA. Food and Drug Administration. Janus kinase (JAK) inhibitors: drug safety communication \u2013 FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death [Internet]. 2021. Accessed 2026 Feb 2. Available from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk."},{"issue":"12","key":"10.1016\/j.ard.2026.06.017_bib0033","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1093\/rheumatology\/keac190","article-title":"Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis","volume":"61","author":"Zhao","year":"2022","journal-title":"Rheumatology (Oxford)."},{"issue":"7","key":"10.1016\/j.ard.2026.06.017_bib0034","first-page":"623","article-title":"Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database","volume":"24","author":"Walsh","year":"2018","journal-title":"J Manag Care Spec Pharm."},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0035","doi-asserted-by":"crossref","first-page":"otac001","DOI":"10.1093\/crocol\/otac001","article-title":"Real-world treatment patterns and physician preferences for biologics in moderate-to-severe inflammatory bowel disease: retrospective chart review in Europe","volume":"4","author":"Huynh","year":"2022","journal-title":"Crohns Colitis 360."},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev."},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0037","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.ard.2026.06.017_bib0038","unstructured":"Standardised MedDRA Queries (SMQs) [Internet]. Accessed 2026 Jan 20. Available from: https:\/\/www.meddra.org\/how-to-use\/tools\/smqs"},{"key":"10.1016\/j.ard.2026.06.017_bib0039","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"10.1016\/j.ard.2026.06.017_bib0040","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2025. Available from: https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.ard.2026.06.017_bib0041","unstructured":"Phillippo DM. multinma: Bayesian Network Meta-Analysis of Individual and Aggregate Data [Internet]. 2025. Available from: https:\/\/cran.r-project.org\/package=multinma."},{"key":"10.1016\/j.ard.2026.06.017_bib0042","unstructured":"Dias S., Welton N.J., Sutton A.J., Ades A.E., NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials [Internet]. Sheffield: Decision Support Unit; 2016. Accessed 2025 Dec 9. Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list."},{"key":"10.1016\/j.ard.2026.06.017_bib0043","series-title":"Network Meta-analysis for Comparative Effectiveness Research","author":"Dias","year":"2018"},{"issue":"7304","key":"10.1016\/j.ard.2026.06.017_bib0044","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ."},{"issue":"7650","key":"10.1016\/j.ard.2026.06.017_bib0045","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"key":"10.1016\/j.ard.2026.06.017_bib0046","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol."},{"issue":"9","key":"10.1016\/j.ard.2026.06.017_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.31204","article-title":"Comparative safety of JAK inhibitors vs TNF antagonists in immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"8","author":"Solitano","year":"2025","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.ard.2026.06.017_bib0048","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ard.2025.05.243","article-title":"OP0232\u2005Cancer incidence among rheumatoid arthritis patients treated with JAK-inhibitors compared to bDMARDs: data from an International Collaboration of Registers (the \u201cJAK-POT\u201d study)","volume":"84","author":"Aymon","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"10.1016\/j.ard.2026.06.017_bib0049","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ard.2025.05.014","article-title":"Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register","volume":"84","author":"Schaefer","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0050","doi-asserted-by":"crossref","first-page":"keaf556","DOI":"10.1093\/rheumatology\/keaf556","article-title":"Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry","volume":"65","author":"Molina-Collada","year":"2026","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"10.1016\/j.ard.2026.06.017_bib0051","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kead163","article-title":"Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study","volume":"63","author":"Westermann","year":"2024","journal-title":"Rheumatology (Oxford)."},{"issue":"4","key":"10.1016\/j.ard.2026.06.017_bib0052","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/joim.20064","article-title":"Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: a nationwide cohort study","volume":"297","author":"Cho","year":"2025","journal-title":"J Intern Med."},{"key":"10.1016\/j.ard.2026.06.017_bib0053","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.annepidem.2023.05.004","article-title":"The application of lag times in cancer pharmacoepidemiology: a narrative review","volume":"84","author":"Hicks","year":"2023","journal-title":"Ann Epidemiol."},{"issue":"7","key":"10.1016\/j.ard.2026.06.017_bib0054","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"10.1016\/j.ard.2026.06.017_bib0055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"10.1016\/j.ard.2026.06.017_bib0056","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"24","key":"10.1016\/j.ard.2026.06.017_bib0057","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hernan","year":"2022","journal-title":"JAMA."},{"issue":"10","key":"10.1016\/j.ard.2026.06.017_bib0058","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of malignancy: results from the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.ard.2026.06.017_bib0059","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","article-title":"Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43,895 trials and 5,685,738 individuals across 989 unique drugs and 286 conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:12:05Z","timestamp":1788174725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726003663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":59,"alternative-id":["S0003496726003663"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.017","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}